Literature DB >> 19749673

Defining cerebral palsy: pathogenesis, pathophysiology and new intervention.

M Longo1, G D V Hankins.   

Abstract

Cerebral palsy (CP) affects 2/1 000 live-born children. There are several antenatal factors, including preterm delivery, low birth weight, infection/inflammation, multiple gestations, and other pregnancy complications, that have been associated with CP in both the preterm and term infant, with birth asphyxia playing a minor role. Due to the increasing survival of the very preterm and very low birth weight infant secondary to improvements in neonatal and obstetric care, the incidence of CP may be increasing. The topics of neonatal encephalopathy and CP, as well as hypoxic-ischemic encephalopathy, are of vital importance to anyone who ventures to deliver infants. Criteria sufficient to define an acute intrapartum hypoxic event as sufficient to cause CP have been advanced previously by both the American College of Obstetricians and Gynecologists and the International Cerebral Palsy Task Force. This review will cover the progression toward defining the pathogenesis and pathophysiology of cerebral palsy. Four essential criteria were advanced as prerequisites if one is to propose that an intrapartum hypoxic-ischemic insult has caused a moderate to severe neonatal encephalopathy that subsequently results in CP. Importantly, all four criteria must be met: 1) evidence of metabolic acidosis (pH <7.0 and base deficit of 12 mmol/L or more); 2) early onset of severe or moderate neonatal encephalopathy in infants born at 34 or more weeks' gestation; 3) CP of the spastic quadriplegic or dyskinetic type, and 4) exclusion of other identifiable etiologies, such as trauma, coagulation disorders, infectious conditions, or genetic disorders. Other criteria that together suggest intrapartum timing are also discussed. The focus of this paper is to explore antenatal antecedents as etiologies of CP and the impact of obstetric care on the prevention of CP.

Entities:  

Mesh:

Year:  2009        PMID: 19749673

Source DB:  PubMed          Journal:  Minerva Ginecol        ISSN: 0026-4784


  9 in total

1.  Anti-IL-6 neutralizing antibody modulates blood-brain barrier function in the ovine fetus.

Authors:  Jiyong Zhang; Grazyna B Sadowska; Xiaodi Chen; Seon Yeong Park; Jeong-Eun Kim; Courtney A Bodge; Erin Cummings; Yow-Pin Lim; Oleksandr Makeyev; Walter G Besio; John Gaitanis; William A Banks; Barbara S Stonestreet
Journal:  FASEB J       Date:  2015-01-21       Impact factor: 5.191

2.  Outcomes of infants with hypoxic-ischemic encephalopathy during COVID-19 pandemic lockdown in Canada: a cohort study.

Authors:  Sujith Kumar Reddy Gurram Venkata; Prakesh S Shah; Marc Beltempo; Eugene Yoon; Stephen Wood; Matthew Hicks; Thierry Daboval; Jonathan Wong; Pia Wintermark; Khorshid Mohammad
Journal:  Childs Nerv Syst       Date:  2022-06-08       Impact factor: 1.532

3.  Hypothermia and other treatment options for neonatal encephalopathy: an executive summary of the Eunice Kennedy Shriver NICHD workshop.

Authors:  Rosemary D Higgins; Tonse Raju; A David Edwards; Denis V Azzopardi; Carl L Bose; Reese H Clark; Donna M Ferriero; Ronnie Guillet; Alistair J Gunn; Henrik Hagberg; Deborah Hirtz; Terrie E Inder; Susan E Jacobs; Dorothea Jenkins; Sandra Juul; Abbot R Laptook; Jerold F Lucey; Mervyn Maze; Charles Palmer; Luann Papile; Robert H Pfister; Nicola J Robertson; Mary Rutherford; Seetha Shankaran; Faye S Silverstein; Roger F Soll; Marianne Thoresen; William F Walsh
Journal:  J Pediatr       Date:  2011-08-27       Impact factor: 4.406

4.  Pilot randomized trial of therapeutic hypothermia with serial cranial ultrasound and 18-22 month follow-up for neonatal encephalopathy in a low resource hospital setting in Uganda: study protocol.

Authors:  Nicola J Robertson; Cornelia F Hagmann; Dominique Acolet; Elizabeth Allen; Natasha Nyombi; Diana Elbourne; Anthony Costello; Ian Jacobs; Margaret Nakakeeto; Frances Cowan
Journal:  Trials       Date:  2011-06-04       Impact factor: 2.279

5.  A clinical study of autologous bone marrow mononuclear cells for cerebral palsy patients: a new frontier.

Authors:  Alok Sharma; Hemangi Sane; Nandini Gokulchandran; Pooja Kulkarni; Sushant Gandhi; Jyothi Sundaram; Amruta Paranjape; Akshata Shetty; Khushboo Bhagwanani; Hema Biju; Prerna Badhe
Journal:  Stem Cells Int       Date:  2015-02-18       Impact factor: 5.443

Review 6.  Tetrahydrobiopterin in antenatal brain hypoxia-ischemia-induced motor impairments and cerebral palsy.

Authors:  Jeannette Vasquez-Vivar; Zhongjie Shi; Kehuan Luo; Karthikeyan Thirugnanam; Sidhartha Tan
Journal:  Redox Biol       Date:  2017-08-03       Impact factor: 11.799

7.  Correlations between risk factors and functional evolution in patients with spastic quadriplegia.

Authors:  O C Rogoveanu; N C Tuțescu; D Kamal; D O Alexandru; C Kamal; L Streba; M R Trăistaru
Journal:  J Med Life       Date:  2016 Apr-Jun

8.  Pattern of Cerebral Palsy Among Sudanese Children Less Than 15 Years of Age.

Authors:  Karimeldin Salih
Journal:  Cureus       Date:  2020-03-10

9.  Therapeutic mechanism of cord blood mononuclear cells via the IL-8-mediated angiogenic pathway in neonatal hypoxic-ischaemic brain injury.

Authors:  Kye Hee Cho; Jee In Choi; Jin-Ock Kim; Joo Eun Jung; Dong-Wook Kim; MinYoung Kim
Journal:  Sci Rep       Date:  2020-03-10       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.